CervoMed Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
CervoMed Inc. (CRVO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 3.20% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-03-17
- CervoMed Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was 3.20%, a 81.29% decline from fiscal 2023.
- CervoMed Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 17.10%, a 1325.00% increase from fiscal 2022.
- CervoMed Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was 1.20%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2024-12-31 | 3.20% 10-K · filed 2025-03-17 |
| 2023-12-31 | 17.10% 10-K · filed 2025-03-17 |
| 2022-12-31 | 1.20% 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |